Kakajan Komurov , PhD

Member, Division of Experimental Hematology & Cancer Biology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-5122

Email kakajan.komurov@cchmc.org

Computational and experimental approaches to characterize targetable cancer vulnerabilities; oncogene-induced stress pathways in cancer therapy; the study of mechanisms, implications and therapeutic vulnerabilities imposed by the severe epigenetic defects in a subset of cancers

Visit the Komurov Lab.

Dr. Komurov's lab focuses on the systems biology of cancer. We develop and employ computational data mining tools to interrogate clinically exploitable cancer mechanisms from cancer genomics data, and use experimental approaches in vitro and in animal models for their molecular characterization. Specifically, we are studying the core aberrations in the genomic, RNA and protein homeostasis networks in cancers, their role in cancer pathogenicity and therapy response, and the synthetic vulnerabilities imposed by these defects on the tumor cell. In addition, we are developing computational methods and software to enable intuitive and effective functional mining of genomic data.
PhD: The University of Texas Southwestern Medical Center, Dallas, TX.

View PubMed Publications

Mohanty V, Akmamedova O, Komurov K. Selective DNA methylation in cancers controls collateral damage induced by large structural variations. Oncotarget. 2016 Jul 8. 

Segura-Cabrera A, Singh N, Komurov K. An integrated network platform for contextual prioritization of drugs and pathways. Mol Biosyst. 2015 Oct 13;11(11):2850-9.

Singh N, Joshi R, Komurov K. HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive. Sci Signal. 2015 May 26;8(378):ra52.

Lane A, Segura-Cabrera A, Komurov K. A comparative survey of functional footprints of EGFR pathway mutations in human cancers. Oncogene. 2014 Oct 23;33(43):5078-89.

Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, Nagrath D, Ram PT. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol. 2012;8:596.

Modeling and targeting the hexosamine pathway in drug resistance. Principal Investigator. Susan G. Komen for the Cure. Aug 2013-Jul 2016. CCR13263034.

Exploiting proteotoxic stress in therapy-refractory HER2+ breast cancers. Principal Investigator. National Cancer Institute. Apr 2015-Mar 2020. 1R01CA193549-01.

Global Transcript Shortening in cancers. Principal Investigator. Cincinnati Children's Hospital Medical Center RIP award. Sep 2015-Aug 2016.